Gilead Sciences (GILD) Current Deferred Revenue (2009 - 2016)

Gilead Sciences (GILD) has reported Current Deferred Revenue for 8 consecutive years, with $202.0 million the latest figure, recorded in Q4 2016.

• For the quarter ending Q4 2016, Current Deferred Revenue fell 54.09% year-over-year to $202.0 million; the trailing twelve-month figure through Dec 2016 stood at $202.0 million (down 54.09% YoY), and the FY2016 full-year result was $202.0 million, down 54.09% from the prior year.
• Current Deferred Revenue declined to $202.0 million in Q4 2016 per GILD's latest filing, from $361.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $529.0 million in Q1 2016 and bottomed at $93.7 million in Q2 2012.
• Historically, Current Deferred Revenue has averaged $214.2 million across 5 years, with a median of $126.8 million in 2013.
• The sharpest annual moves came in 2015 and 2016: Current Deferred Revenue soared 296.72% in 2015, then sank 54.09% in 2016.
• Over 5 years, Current Deferred Revenue stood at $103.2 million in 2012, then rose by 7.6% to $111.0 million in 2013, then gained by 20.72% to $134.0 million in 2014, then jumped by 228.36% to $440.0 million in 2015, then tumbled by 54.09% to $202.0 million in 2016.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $202.0 million, $361.0 million, and $345.0 million for Q4 2016, Q3 2016, and Q2 2016 respectively.